Anteris Technologies Global Corp. — Capital/Financing Update 2024

Apr 9, 2024

==> picture [192 x 28] intentionally omitted <==

ASX ANNOUNCEMENT

10 April 2024

Anteris Raises $23 Million

Brisbane, Australia and Minneapolis, USA

Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) has placed one million new ordinary shares at $23 each, raising $23 million in gross proceeds.

The funds raised will primarily be used preparing for the DurAVR™ transcatheter heart valve’s FDA pivotal study, a key step to gain regulatory clearance for the US market.

The funds will also be used for strategic initiatives, valve-in-valve trials and general working capital.

The new shares were issued from the Company’s available placement capacity under Listing Rule 7.1.

DurAVR™ has been implanted in 50 patients (44 with severe aortic stenosis and six valve-in-valve cases to rectify prosthetic valve failure). Clinical results to date demonstrate this new class of biomimetic valve outperforms the market leader, returning patients to a near normal haemodynamic (blood flow) state.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company’s lead product, DurAVR[TM] , is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR[TM] THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR[TM] THV is made using ADAPT[®] tissue, Anteris’ patented anti-calcification tissue technology. ADAPT[®] tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR[TM] Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR[TM] THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

==> picture [41 x 40] intentionally omitted <==

REGISTERED OFFICE Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD 4066 Australia

T: +61 1300 550 310 info.au@anteristech.com anteristech.com

BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

==> picture [195 x 28] intentionally omitted <==

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations

investors@anteristech.com Anteris Technologies Ltd +61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D., Managing Director Blueprint Life Science Group +1 917 330 4269

Website www.anteristech.com Twitter @AnterisTech Facebook www.facebook.com/AnterisTechnologies LinkedIn https://www.linkedin.com/company/anteristech

==> picture [41 x 40] intentionally omitted <==